Halozyme Therapeutics (HALO) Earnings Date & Reports

Key Takeaways

• Halozyme Therapeutics (HALO) is scheduled to report second quarter 2026 results on Thursday, August 6, 2026, after the market close.
• Consensus estimates point to earnings per share (EPS) in the range of $1.72 to $1.81, with revenue expectations clustering between approximately $401 million and $414 million.
• The year-ago quarter (Q2 2025) delivered EPS of $1.54 on revenue of $325.72 million, meaning expectations imply year-over-year revenue growth of roughly 23% to 27%.
• Halozyme enters the quarter with reaffirmed full-year 2026 guidance calling for total revenue of $1.71 billion to $1.81 billion and non-GAAP (Generally Accepted Accounting Principles) diluted EPS of $7.75 to $8.25.
• ENHANZE royalty revenue — the company's core growth driver — is projected to exceed $1 billion for the full year, a milestone management has described as arriving one year earlier than originally anticipated.
• Analyst consensus remains a Moderate Buy with an average price target near $81.60, though individual estimates range widely depending on assumptions around royalty cadence and deal flow.

Earnings Context and Why It Matters

Halozyme's Q2 2026 report lands at a pivotal moment for the biopharmaceutical company. In January, management raised full-year 2026 guidance across every major metric — total revenue, royalty revenue, adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), and non-GAAP EPS — citing exceptional momentum in its ENHANZE drug delivery platform. Q1 2026 results validated that optimism, with total revenue jumping 42% year-over-year to $376.71 million and royalty revenue climbing 43% to $241 million. This quarter will test whether that trajectory is sustainable. Investors will be watching closely to see if partner product sales — particularly DARZALEX FASPRO, VYVGART Hytrulo, and PHESGO — continue delivering the double-digit royalty growth that underpins Halozyme's model, while also gauging early contributions from newer launches such as RYBREVANT SC.

Earnings Expectations

Wall Street's expectations for Halozyme's second quarter reflect cautious optimism. Consensus EPS estimates range from approximately $1.72 (Zacks Research) to $1.81 (FactSet), with revenue projections clustering between roughly $401 million and $414 million. For context, Halozyme reported Q2 2025 EPS of $1.54 on revenue of $325.72 million, meaning the midpoint of current estimates implies year-over-year top-line growth approaching 25%. H.C. Wainwright, which maintains a Buy rating and a $95 price target, projects Q2 revenue of $412 million — including $273 million in royalties — and EPS of $1.65, slightly below the broader Street consensus.

Beyond the headline numbers, analysts will focus on several key metrics: the quarter-over-quarter trajectory of ENHANZE royalty revenue (which reached $241 million in Q1), gross margin trends within the legacy product sales segment, and any updates to partner product conversion rates. The company's ability to maintain adjusted EBITDA margins above 65% — a target reaffirmed on the Q1 call — will also be scrutinized. Notably, management's FY 2026 guidance ranges remain wide enough to absorb some quarterly variability, but a miss on royalty revenue expectations would likely raise questions about the pace of subcutaneous conversion across Halozyme's partner portfolio.

AI Screener

For investors seeking to identify opportunities across the biotech and pharmaceutical landscape beyond individual names like Halozyme, Tickeron's AI Screener offers a powerful, AI-driven approach to stock and ETF discovery. The platform enables users to filter thousands of securities using customizable criteria such as industry classification, market capitalization, technical indicators, price patterns, volatility metrics, and AI-generated trading signals. By automating much of the manual research process, the AI Screener helps traders and investors surface breakout candidates, trending stocks, and high-conviction trade ideas more efficiently than traditional screening methods. Whether you are tracking earnings season catalysts or scanning for longer-term thematic plays, the screener can help narrow the field with precision and speed.

Market Reaction and Investor Sentiment

Investor sentiment heading into Halozyme's Q2 report is broadly constructive but measured. The stock carries a Moderate Buy consensus from 13 analysts, with eight Buy ratings, four Holds, and one Sell. Price targets span a wide range — from $65 to $95 — reflecting divergent views on the durability of ENHANZE-driven royalty streams beyond the current wave of approved products. Historical trading patterns around earnings show mixed reactions: Q1 2026's beat prompted a modest 0.08% move, while Q4 2025 — which featured a large GAAP loss driven by one-time acquisition-related charges — triggered a 10% decline. Q3 2025, by contrast, rallied more than 6% following an earnings beat. The stock's reaction to Q2 results will likely hinge on royalty revenue momentum and any adjustments to full-year guidance, particularly given that management has already met its 2026 target of three new collaboration agreements and may signal whether additional deals are in the pipeline.

Forward Outlook and Key Factors to Monitor

After this earnings event, investors should focus on several interconnected themes that will shape Halozyme's growth narrative through the remainder of 2026 and beyond.

First is the ENHANZE royalty backlog. Management estimates that only about 25% of the total projected royalties from the 10 currently approved ENHANZE products had been realized by the end of 2025, with roughly 66% of the remaining opportunity concentrated in the 2026–2032 window. This implies a long runway of visible, contract-backed revenue growth — but realizing it depends on continued adoption of subcutaneous formulations by physicians and patients globally. Any commentary from partners such as Johnson & Johnson, Roche, and argenx about conversion rates or competitive dynamics will be closely parsed.

Second, the Hypercon platform is entering a critical development phase. Management recently adjusted the timeline for the first two Phase 1 clinical starts to the first half of 2027, a modest delay from the prior expectation of late 2026. Five Hypercon agreements covering 17 potential targets have already been signed, and the company projects this platform could generate roughly $1 billion in annual royalty revenue by the mid-2030s. However, the manufacturing scale-up and clinical execution risk remain open questions that the market will want clarity on.

Third, capital allocation strategy deserves attention. Halozyme announced a $1 billion share repurchase authorization in May and expects to buy back at least $400 million in stock during 2026. With net leverage projected to decline from approximately 2.5x to roughly 1.2x by year-end, the company appears to be balancing shareholder returns with continued investment in its drug delivery portfolio. Whether the buyback pace accelerates or moderates based on cash flow generation will be an important signal.

Finally, the regulatory and competitive landscape continues to evolve. In June, Halozyme stated that a newly proposed Medicare Drug Price Negotiation Program rule would have zero to minimal impact on royalty revenue through at least 2035. Meanwhile, the long-term patent cliff for certain ENHANZE-enabled products — particularly as base patents approach expiration around 2029 — remains a structural consideration that management is addressing through co-formulation patent strategies designed to extend royalty duration.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations